Market Cap: $15.52B
AA
Ascendis Pharma A/S
ASND
NASDAQ (NASDAQ Global Select)USD
Market Cap: $15.52B
Regulatory Success: Yuviwel Approval Marks a Major Milestone for Ascendis Pharma Ascendis Pharma A/S achieves a significant milestone with the recent approval of Yuviwel (navepegritide) by the U.S. Fo…
Ascendis Pharma Secures FDA Approval for Yuviwel, Advancing Pediatric Care for Achondroplasia Ascendis Pharma A/S achieves a significant milestone with the recent U.S. Food and Drug Administration (FD…
Yuviwel’s FDA Approval Marks a Milestone for Ascendis Pharma in Pediatric Treatment Ascendis Pharma A/S achieves a significant breakthrough with the recent approval from the U.S. Food and Drug Adminis…
Ascendis Pharma's Short Interest Surge: Implications for the Biotech Sector Ascendis Pharma A/S, a biotechnology company focused on innovative treatments, faces a significant rise in short interest, w…
Ascendis Pharma Sees Spike in Short Interest Amid Market Speculation Ascendis Pharma A/S, a biopharmaceutical company known for its innovative therapies, experiences a significant increase in short in…
Ascendis Pharma A/S: Pioneering Innovations in Endocrine Therapies Ascendis Pharma A/S continues to capture attention in the biotech arena due to its commitment to developing innovative therapies for…
Innovative Therapies: Ascendis Pharma's Commitment to Endocrine Diseases Ascendis Pharma A/S stands at the forefront of biotechnology, particularly in the development of therapies aimed at treating en…
FDA Extends Review of Ascendis Pharma’s TransCon CNP for Achondroplasia Treatment The U.S. Food & Drug Administration (FDA) has announced an extension of its review process for Ascendis Pharma A/S’ Ne…
### Ascendis Pharma Faces Extended FDA Review for TransCon CNP Ascendis Pharma A/S is currently navigating a pivotal moment in its regulatory journey as the U.S. Food & Drug Administration (FDA) exten…
Ascendis Pharma Faces Increased Short Selling Amid Market Caution Ascendis Pharma A/S is currently navigating through a challenging landscape marked by a notable rise in short interest, which has surg…
Ascendis Pharma Faces Growing Short Interest Amid Investor Caution Ascendis Pharma A/S, a biotechnology firm focused on developing innovative therapies, finds itself under increased scrutiny as its sh…
### Ascendis Pharma A/S: Navigating the Evolving Biopharmaceutical Landscape Ascendis Pharma A/S stands at a pivotal juncture in the biopharmaceutical industry, particularly as the company continues t…
Ascendis Pharma Gears Up for Earnings Call Amidst Strategic Developments Ascendis Pharma A/S prepares to announce its quarterly earnings on November 12, 2025, a pivotal moment that is expected to shed…
Ascendis Pharma Gears Up for Key Earnings Announcement Amidst Strategic Developments As Ascendis Pharma A/S approaches its quarterly earnings announcement scheduled for November 12, 2025, the focus sh…
Ascendis Pharma Faces Increased Short Interest Amid Market Sentiment Ascendis Pharma A/S, a biotechnology firm specializing in innovative therapies, encounters a significant rise in short interest, wh…
Ascendis Pharma Faces Rising Short Interest Amid Market Sentiment Shift Ascendis Pharma A/S, a biopharmaceutical company focused on innovative therapies, is currently experiencing a notable rise in sh…
Ascendis Pharma Sees Decrease in Short Interest, Indicating Shifts in Market Sentiment Ascendis Pharma A/S is currently navigating a notable shift in market sentiment as its short interest declines. R…
Ascendis Pharma A/S Sees Shift in Short Selling Dynamics Ascendis Pharma A/S, a biopharmaceutical company focused on developing innovative therapies, experiences a significant change in its short inte…
Ascendis Pharma Experiences Significant Shift in Short Interest Dynamics Ascendis Pharma A/S, a biotechnology company specializing in innovative therapies, witnesses a noteworthy decrease in its short…
Innovative Advances in Genetic Disorder Treatments Ascendis Pharma A/S operates within the competitive landscape of biopharmaceuticals, focusing on transformative therapies for rare diseases. The rece…
BioMarin's Breakthrough in Genetic Disorder Treatment: A Paradigm Shift in Biopharmaceuticals BioMarin Pharmaceutical Inc. (BMRN) is making headlines with the recent announcement of impressive results…
Innovative Advances in Genetic Disorder Treatments: Insights from BioMarin's PEGASUS Study BioMarin Pharmaceutical Inc. (BMRN) has recently unveiled promising results from its Phase 3 PEGASUS study, w…
Ascendis Pharma Sees Reduced Short Interest, Indicating Optimism in Market Sentiment Ascendis Pharma A/S experiences a significant decrease in short interest, signaling a potential shift in market dyn…
Ascendis Pharma's Short Interest Decline Signals Optimism in Market Sentiment Ascendis Pharma A/S experiences a significant shift in market sentiment as it reports a notable decrease in short interest…
Ascendis Pharma Sees Decrease in Short Interest, Reflecting Optimism in Market Sentiment Ascendis Pharma A/S experiences a significant decline in short interest, as recent data shows a 9.85% drop in t…
Ascendis Pharma A/S Sees Significant Shift in Short Interest Trends Ascendis Pharma A/S experiences a notable decrease in short interest, signaling a potential shift in trader sentiment towards the co…
Ascendis Pharma Experiences Shift in Short Selling Sentiment Ascendis Pharma A/S, a biopharmaceutical company focused on developing innovative therapies for rare diseases, is witnessing a notable decl…
Ascendis Pharma Experiences Declining Short Interest Amid Market Dynamics Ascendis Pharma A/S is currently witnessing a notable decrease in short interest, indicating a potential shift in investor sen…
Ascendis Pharma Partners with Orsini to Enhance Access to YORVIPATH® for Chronic Hypoparathyroidism Patients Ascendis Pharma A/S has established a significant partnership with Orsini, a recognized lea…